Home    Back

256. Muscle glycogenosis
161 clinical trials,   114 drugs   (DrugBank: 23 drugs),   26 drug target genes,   106 drug target pathways

Searched query = "Muscle glycogenosis", "Muscular glycogenosis", "Muscle glycogen storage disease", "Muscular glycogen storage disease", "Glycogen storage disease type ... show all
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2019-001283-30-DE
(EUCTR)		20/08/202020/01/2020A study of safety, tolerability and efficacy of a single intravenous infusion of SPK-3006 in adults with late-onset Pompe disease (type II glycogen storage disease)Phase 1/2, dose-escalation study to evaluate the safety, tolerability and efficacy of a single intravenous infusion of SPK-3006 in adults with late-onset Pompe disease Pompe Disease (also known as glycogen storage disease type II)
MedDRA version: 20.1;Level: PT;Classification code 10053185;Term: Glycogen storage disease type II;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]		Product Code: SPK-3006
INN or Proposed INN: SPK-3006		Spark TherapeuticsNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		20Phase 1;Phase 2United States;France;Netherlands;Germany;United Kingdom;Italy
2EUCTR2019-001283-30-FR
(EUCTR)		16/06/202018/09/2019A study of safety, tolerability and efficacy of a single intravenous infusion of SPK-3006 in adults with late-onset Pompe disease (type II glycogen storage disease)Phase 1/2, dose-escalation study to evaluate the safety, tolerability and efficacy of a single intravenous infusion of SPK-3006 in adults with late-onset Pompe disease Pompe Disease (also known as glycogen storage disease type II)
MedDRA version: 20.1;Level: PT;Classification code 10053185;Term: Glycogen storage disease type II;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]		Product Code: SPK-3006
INN or Proposed INN: SPK-3006		Spark TherapeuticsNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		20Phase 1;Phase 2United States;France;Netherlands;Germany;United Kingdom;Italy